natgillin/translations-raw huggingface dataset:
The main measure of effectiveness was the number of patients who had at least a ‘major cytogenetic response’ (where the proportion of white blood cells with the Philadelphia chromosome fell below 35%) after six months of Bosulif treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so imeli najmanj „pomembni citogenični odziv‟ (kadar je delež belih krvničk s kromosomom Philadelphia padel pod 35 %) po šestih mesecih zdravljenja z zdravilom Bosulif.
The main measure of effectiveness was the number of patients who had complete remission.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih je bila dosežena popolna remisija.
The main measure of effectiveness was the number of patients who had completely stopped smoking for four weeks (between week 9 and week 12 of the study), confirmed by laboratory testing of the patients’ breath for signs of smoking.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so za štiri tedne (med 9. in 12. tednom študije) popolnoma opustili kajenje, kar so preverjali z laboratorijskimi preiskavami izdihanega zraka bolnikov, v katerem so iskali znake kajenja.
The main measure of effectiveness was the number of patients who had either a DVT recurrence or pulmonary embolism.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih sta DVT ali pljučna embolija ponovno nastopila.
The main measure of effectiveness was the number of patients who had either a stroke or a blood clot in a blood vessel.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so utrpeli bodisi možgansko kap bodisi so imeli krvni strdek v žili.
The main measure of effectiveness was the number of patients who had no detectable virus in their blood 24 weeks after the end of the treatment and could therefore be considered to be cured.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih 24 tednov po zaključku zdravljenja v krvi ni bilo zaznanega virusa, kar pomeni, da so bili ozdravljeni.
The main measure of effectiveness was the number of patients who had undetectable levels of HIV-1 in their blood (below 400 copies/ml) after treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih so bile ravni virusa HIV-1 v krvi po zdravljenju nezaznavne (pod 400 kopij/ml).
The main measure of effectiveness was the number of patients who reported a significant improvement in their quality of sleep and ability to function normally on the following day, after three weeks of treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so po treh tednih zdravljenja občutili bistveno izboljšanje kakovosti spanja in sposobnosti normalnega delovanja naslednji dan.
The main measure of effectiveness was the number of patients who responded to Revolade (whose platelet, red or white blood cell count remained above pre-set levels) after 12 or 16 weeks of treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so se po 12 ali 16 tednih zdravljenja odzvali na zdravilo Revolade (pri katerih je število trombocitov ter rdečih in belih krvnih telesc ostalo nad predhodno določenimi ravnmi).
The main measure of effectiveness was the number of patients who responded to treatment at week eight, after having received three infusions with Remicade.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so se po osmem tednu, ko so prejeli tri infuzije zdravila Remicade, odzvali na zdravljenje.
The main measure of effectiveness was the number of patients who showed an improvement of at least 1 point on a 10-point scale of disability in their arms and legs.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih je prišlo do izboljšanja stanja v okončinah za vsaj 1 točko na 10-stopenjski lestvici prizadetosti.
The main measure of effectiveness was the number of patients who went into ‘remission’ (clearance of leukaemia from the bone marrow and complete or partial recovery of blood cell counts to normal levels).
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih je bila dosežena remisija (očistek levkemije iz kostnega mozga in popolno ali delno povečanje števila krvnih celic na normalne ravni).
The main measure of effectiveness was the number of patients who ‘responded’ after at least five weeks of treatment.
Glavno merilo učinkovitosti je bilo število bolnic, ki so se odzvale na zdravljenje po najmanj petih tednih zdravljenja.
The main measure of effectiveness was the number of patients who ‘responded’ to treatment after 12 weeks, meaning that symptom scores improved by 75% or more.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so se po 12 tednih odzvali na zdravljenje, kar pomeni, da so se ocene njihovih simptomov izboljšale za najmanj 75 %.
The main measure of effectiveness was the number of patients who ‘responded’ to treatment.
Glavno merilo učinkovitosti je bil število bolnikov, ki so se odzvali na zdravljenje.
The main measure of effectiveness was the number of patients who ‘responded’ to treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so se „odzvali“ na zdravljenje.
The main measure of effectiveness was the number of patients whose blood cells no longer contained the Philadelphia chromosome within one year of treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih krvne celice po enoletnem zdravljenju niso več vsebovale kromosoma Philadelphia.
The main measure of effectiveness was the number of patients whose disability got worse.
Glavno merilo učinkovitosti je bilo število bolnikov, katerih prizadetost se je poslabšala.
The main measure of effectiveness was the number of patients whose final three blood uric acid levels were below 6 mg/dl.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih so bile ravni sečne kisline pri zadnjih treh meritvah nižje od 6 mg/dl.
The main measure of effectiveness was the number of patients whose symptoms of depression came back after treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih so se simptomi depresije po končanem zdravljenju ponovili.
The main measure of effectiveness was the number of patients whose ‘best corrected visual acuity’ (BCVA) had improved enough after 90 or 180 days so that they could read at least 15 more letters in a standard eye test.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se je najboljša korigirana ostrina vida (BCVA) po 90 ali 180 dneh toliko izboljšala, da so lahko med standardnim testom vida prebrali vsaj 15 črk več.
The main measure of effectiveness was the number of patients with an increase in ‘on’ time of one hour or more, during the three weeks following the switch.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se je vključitveno obdobje podaljšalo za eno uro ali več v treh tednih, ki so sledili prehodu na drugo zdravilo.
The main measure of effectiveness was the number of patients with no signs of inflammation after two weeks.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih po dveh tednih zdravljenja ni bilo več znakov vnetja.
The main measure of effectiveness was the number of relapses that patients experienced over 1 year but the study also looked at other measures including how fast the patients’ disability progressed.
Glavno merilo učinkovitosti je bilo število relapsov pri bolnikih v prvem letu, študija pa je proučevala tudi druga merila, vključno s hitrostjo napredovanja bolnikove nezmožnosti/invalidnosti.
The main measure of effectiveness was the number of relapses that the patients had.
Glavno merilo učinkovitosti je bilo število zagonov, ki so jih imeli bolniki.
The main measure of effectiveness was the number of seizures in a month.
Glavno merilo učinkovitosti je bilo število epileptičnih napadov v enem mesecu.
The main measure of effectiveness was the number of serious bacterial infections and the amount of antibiotic used.
Glavno merilo učinkovitosti je bilo število resnih bakterijskih okužb in količina uporabljenih antibiotikov.
The main measure of effectiveness was the number of serious bacterial infections over a year’s treatment.
Glavno merilo učinkovitosti je bilo število resnih bakterijskih okužb v obdobju enoletnega zdravljenja.
The main measure of effectiveness was the number of women aged 18 to 35 who became pregnant during or shortly after treatment, expressed in terms of a pregnancy rate using the ‘Pearl Index’.
Glavno merilo učinkovitosti je bilo število žensk v starosti od 18 do 35 let, ki so zanosile med prejemanjem zdravila ali kmalu po njem, izraženo s stopnjo nosečnosti ob uporabi „Pearlovega indeksa“.
The main measure of effectiveness was the number of women aged 18 to 35 who became pregnant during or shortly after treatment, expressed in terms of a pregnancy rate using the ‘Pearl Index’.
Glavno merilo učinkovitosti je bilo število žensk v starosti od 18 do 35 let, ki so zanosile v času jemanja zdravila ali kmalu po njegovem prenehanju, izraženo s stopnjo nosečnosti ob uporabi „Pearlovega indeksa“.
The main measure of effectiveness was the number of women who became pregnant.
Glavno merilo učinkovitosti je bilo število žensk, ki so zanosile.
The main measure of effectiveness was the percentage of patients who experienced at least a 50% decrease in seizure frequency.
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih je pogostost napadov padla za vsaj 50 %.
The main measure of effectiveness was the percentage of patients who were able to adjust to the 24-hour clock, which was calculated by looking at how the amount of melatonin breakdown products changed in the patient’s urine over time.
Glavno merilo učinkovitosti je bil odstotek bolnikov, ki so se uspeli prilagoditi na 24-urni dan, kar so izračunali s pomočjo določanja, kako se je količina produktov razgradnje melatonina v urinu bolnikov spreminjala s časom.
The main measure of effectiveness was the percentage of the rabbits that died as a result of ERE between days 0 - 28.
Glavno merilo učinkovitosti je bil odstotek kuncev, ki so poginili zaradi ERE v obdobju od 0–28 dni.
The main measure of effectiveness was the percentage of women who had no more than one day of spotting (minimal uterine bleeding) within a 35-day interval.
Glavno merilo učinkovitosti je bil delež žensk, ki so v 35 dneh krvavele samo en dan (minimalna krvavitev iz maternice).
The main measure of effectiveness was the presence of antibodies against the viruses in the vaccinated kittens’ blood.
Glavno merilo učinkovitosti je bila prisotnost protiteles proti virusom v krvi cepljenih mladičev.
The main measure of effectiveness was the prevention of premature LH production.
Glavno merilo učinkovitosti je bila preprečitev prezgodnjega tvorjenja LH.
The main measure of effectiveness was the production of protective antibodies against C. perfringens type A in the chickens’ blood and in their eggs.
Glavno merilo učinkovitosti je bila proizvodnja zaščitnih protiteles proti C. perfringens tipa A v krvi in jajcih kokoši.
The main measure of effectiveness was the production of protective antibodies in the infants.
Glavno merilo učinkovitosti je bila tvorba zaščitnih protiteles pri otrocih.
The main measure of effectiveness was the proportion of deep partial thickness wounds that needed surgery to remove further skin tissue or that required a skin graft from another area of the patient’s body.
Glavno merilo učinkovitosti je bil odstotek globokih dermalnih ran, pri katerih je bilo treba s kirurškim posegom odstraniti dodatno kožno tkivo ali izvesti presaditev kože z drugega predela bolnikovega telesa.
The main measure of effectiveness was the proportion of patients who achieved at least a 20% reduction in ACR scores (a measure of painful, swollen joints and other symptoms) after 24 weeks of treatment.
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih je po 24 tednih zdravljenja prišlo do najmanj 20- odstotnega zmanjšanja vrednosti ACR (merilo za boleče, otekle sklepe in druge simptome).
The main measure of effectiveness was the proportion of patients who achieved at least a 20% reduction in ACR scores (a measure of painful, swollen joints and other symptoms) after 30 weeks of treatment.
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih je po 30 tednih zdravljenja prišlo do najmanj 20- odstotnega zmanjšanja rezultata ACR (merilo za boleče, otekle sklepe in druge simptome).
The main measure of effectiveness was the proportion of patients who died or had an ‘ischaemic event’ (restriction of blood supply to an organ, including the heart).
Glavno merilo učinkovitosti je bil delež bolnikov, ki so umrli ali so imeli „ishemični dogodek“ (omejitev dotoka krvi do organov, vključno do srca).
The main measure of effectiveness was the proportion of patients who had had a ‘major molecular response’ (when the proportion of the patient’s white blood cells that contained the Philadelphia chromosome had fallen to below 0.1%) after 12 months of treatment.
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih je po 12 mesecih zdravljenja prišlo do pomembnega citogenetičnega odziva (delež bolnikovih belih krvnih celic, ki so vsebovale kromosom Philadelphia, je padel pod 0,1 %).
The main measure of effectiveness was the proportion of patients who maintained vision (defined as losing less than 15 letters in a standard eye test) after the first year of treatment.
Glavno merilo učinkovitosti je bil delež bolnikov, ki so ohranili vid (kar je bilo opredeljeno kot zmanjšanje števila pravilno prebranih črk za manj kot 15 črk pri standardnem očesnem testu) po prvem letu zdravljenja.
The main measure of effectiveness was the proportion of patients who no longer had the bacteria in their sputum (phlegm).
Glavno merilo učinkovitosti je bil delež bolnikov, ki v izpljunku (sputumu) niso imeli več bakterij.
The main measure of effectiveness was the proportion of patients who responded completely or partially to treatment (as measured by the disappearance of or at least a 50% reduction in a protein found in excess in multiple myeloma cells).
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se popolnoma ali delno odzvali na zdravljenje (merilo je bila odsotnost ali vsaj 50-odstotno zmanjšanje beljakovine, ki je v veliki meri prisotna v celicah multiplega mieloma).
The main measure of effectiveness was the proportion of patients who responded to treatment (objective response rate) and whose tumour shrank, which was assessed using body scans and standardised criteria for solid tumours.
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se odzvali na zdravljenje (objektivna stopnja odziva) in pri katerih se je tumor zmanjšal, kar so ocenjevali s slikanjem telesa in standardiziranimi kriteriji za solidne tumorje.
The main measure of effectiveness was the proportion of patients who responded to treatment and for whom the response lasted for at least six months before the patients’ health declined or they required another therapy.
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se odzvali na zdravljenje in pri katerih je odziv trajal vsaj šest mesecev, preden se je bolnikovo zdravstveno stanje poslabšalo ali je potreboval drugo vrsto zdravljenja.
The main measure of effectiveness was the proportion of patients who responded to treatment and whose brain tumour shrank by at least half after six months of treatment.
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se odzvali na zdravljenje in katerih tumorji so se po šestih mesecih zdravljenja zmanjšali vsaj za polovico.
The main measure of effectiveness was the proportion of patients who responded to treatment and whose kidney tumour shrank by at least half.
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se odzvali na zdravljenje in katerih tumorji so se zmanjšali vsaj za polovico.
The main measure of effectiveness was the proportion of patients who responded to treatment, defined as no evidence of disease and recovery of blood cell counts, within a month of starting Atriance treatment.
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se v času enega meseca od začetka zdravljenja z zdravilom Atriance odzvali nanj, pri čemer je bil odziv opredeljen kot odsotnost znakov bolezni in izboljšanje krvne slike.
The main measure of effectiveness was the proportion of patients who responded to treatment.
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se odzvali na zdravljenje.
The main measure of effectiveness was the proportion of patients who were cured at the end of treatment as determined by a reduction in symptoms, or who had ‘satisfactory’ reductions in the amount of bacteria detected in samples taken from the throat.
Glavno merilo učinkovitosti je bil delež bolnikov, ki so ob koncu zdravljenja ozdraveli, kakor je pokazalo zmanjšanje simptomov, oziroma delež bolnikov z zadovoljivim zmanjšanjem količine bakterij, odkritih v vzorcih, vzetih iz grla.
The main measure of effectiveness was the proportion of patients who ‘responded’ to treatment after 12 weeks, meaning that symptom scores improved by 75% or more.
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se po 12 tednih odzvali na zdravljenje, kar je pomenilo, da so se ocene simptomov izboljšale za 75 % ali več.
The main measure of effectiveness was the proportion of patients whose cortisol level in the urine normalised after six months.
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih se je koncentracija kortizola v urinu po šestih mesecih normalizirala.
The main measure of effectiveness was the proportion of patients whose heart rhythm returned to normal.
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih se je srčni utrip normaliziral.
The main measure of effectiveness was the proportion of patients whose HIV-1 levels in the blood (viral loads) had fallen below a defined level.
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih so ravni virusa HIV-1 (virusna obremenitev) v krvi padle pod določeno raven.
The main measure of effectiveness was the proportion of patients with a reduction of the levels of virus in the blood (viral load) to fewer than 50 copies of HIV RNA per ml, which was 68.8%.
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih se je raven virusa v krvi (virusno breme) zmanjšala pod 50 kopij HIV RNA na ml, znašal pa je 68,8 %.
The main measure of effectiveness was the rate of weight gain in the vaccinated pigs, but the studies also looked at other parameters including symptoms, the level of PCV2 in the blood and the number of runts.
Glavno merilo učinkovitosti je bila hitrost pridobivanja telesne mase pri cepljenih prašičih, vendar so v študijah preverjali tudi druge parametre, vključno s simptomi, ravnijo PCV2 v krvi in številom živali, ki zaostajajo v rasti.
The main measure of effectiveness was the reduction in number of patients who needed a blood transfusion.
Glavno merilo učinkovitosti je bilo zmanjšanje števila bolnikov, ki so potrebovali transfuzijo krvi.
The main measure of effectiveness was the reduction in the level of cholesterol after 12 weeks (excluding HDL or ‘good’ cholesterol).
Glavno merilo učinkovitosti je bilo znižanje ravni holesterola po 12 tednih (brez holesterola HDL ali „dobrega“ holesterola).
The main measure of effectiveness was the reduction in the levels of HIV in the blood (viral load) after 16 weeks; a third study involved 566 patients who had not taken HIV treatment before and compared Isentress with efavirenz (another anti-HIV medicine).
Glavno merilo učinkovitosti je bilo znižanje ravni virusa HIV v krvi (virusnega bremena) po 16 tednih; v tretjo študijo je bilo vključenih 566 odraslih bolnikov, ki predhodno niso jemali zdravil za zdravljenje okužbe z virusom HIV, v njej pa so zdravilo Isentress primerjali z efavirenzom (drugim zdravilom za zdravljenje okužbe z virusom HIV).
The main measure of effectiveness was the reduction in the levels of HIV in the blood (viral load) after 24 weeks.
Glavno merilo učinkovitosti je bilo znižanje ravni virusa HIV v krvi (virusnega bremena) po 24 tednih.
The main measure of effectiveness was the reduction in the number of relapses.
Glavno merilo učinkovitosti je bilo zmanjšanje števila recidivov.
The main measure of effectiveness was the risk of clinical failure (the patients’ disease getting worse).
Glavno merilo učinkovitosti je bilo tveganje kliničnega neuspeha (poslabšanja bolnikovega stanja).
The main measure of effectiveness was the time it took for patients to develop MS, using standard criteria for diagnosing MS.
Glavno merilo učinkovitosti je bil čas, v katerem se je pri bolnikih razvila multipla skleroza, pri čemer so za ocenjevanje uporabljali standardno lestvico za diagnosticiranje multiple skleroze.
The main measure of effectiveness was the time spent in the ‘off’ state during the day, as recorded in patients’ diaries.
Glavno merilo učinkovitosti je bil čas preživet v stanju „off“ v teku dneva, kot je bilo zabeleženo v bolnikovem dnevniku.
The main measure of effectiveness was the time spent in the ‘on’ state (the time when levodopa is controlling the symptoms of Parkinson’s disease) after the first levodopa dose of the morning in the first study, and over one day in the second study.
Glavno merilo učinkoitosti je bil čas, ko je bilo bolnikovo stanje dobro (stanje „vklopa“, ko je levodopa nadzorovala simptome Parkinsonove bolezni), in sicer po prvem jutranjem odmerku levodope v prvi študiji in v teku celega dne v drugi študiji.
The main measure of effectiveness was the time spent in the ‘on’ state (the time when levodopa is controlling the symptoms of Parkinson’s disease) after the first levodopa dose of the morning in the first study, and over one day in the second study.
Glavno merilo učinkovitosti je bil čas, ko je bilo bolnikovo stanje dobro (stanje „vklopa“, ko je levodopa nadzorovala simptome Parkinsonove bolezni), in sicer po prvem jutranjem odmerku levodope v prvi študiji in v teku celega dne v drugi študiji.
The main measure of effectiveness was the time until death due to disease of the heart or blood vessels, or hospitalisation due to worsening heart failure.
Glavno merilo učinkovitosti je bil čas do smrti zaradi bolezni srca ali ožilja ali do hospitalizacije zaradi poslabšanja srčnega popuščanja.
The main measure of effectiveness was the time until death due to disease of the heart or blood vessels, or hospitalisation due to worsening heart failure.
Glavno merilo učinkovitosti je bil čas do smrti zaradi bolezni srca ali ožilja oziroma do hospitalizacije zaradi poslabšanja srčnega popuščanja.
The main measure of effectiveness was the viral load (the level of HIV in the patient’s blood) after 24 weeks of treatment.
Glavno merilo učinkovitosti je bilo virusno breme (raven virusa HIV v krvi bolnikov) po 24 tednih zdravljenja.
The main measure of effectiveness was time until the disease got worse or, for Kaposi’s sarcoma, the number of patients who responded to treatment.
Glavno merilo učinkovitosti je bil čas do poslabšanja bolezni, pri Kaposijevem sarkomu pa število bolnikov, ki so se odzvali na zdravljenje.
The main measure of effectiveness was whether Nimenrix was as good as the comparator vaccines at stimulating an immune response against the four types of N. meningitidis polysaccharides showing an ability to kill the bacteria.
Glavno merilo učinkovitosti je bila sposobnost cepiva Nimenrix, da spodbudi enako dober imunski odziv proti štirim vrstam polisaharidov bakterije N. meningitidis kot primerjalna cepiva, kar kaže na sposobnost, da lahko uniči bakterije.
The main measure of effectiveness, which was studied in 6,000 babies, was the number of babies who developed rotavirus gastroenteritis during the following rotavirus season (the time of the year when rotaviruses are known to circulate and cause infection, generally during the cooler months in winter to early spring).
Glavno merilo učinkovitosti, ki so ga proučevali pri 6 000 dojenčkih, je bilo število otrok, pri katerih se je v naslednji rotavirusni sezoni (obdobju v letu, ko se pričakuje širjenje rotavirusov in pojav okužb, po navadi v hladnejših mesecih – od zime do zgodnje pomladi) pojavil rotavirusni gastroenteritis.
The main measure of the immune response was the level of antibodies against PCV2 in the piglets’ blood.
Glavno merilo imunskega odziva je bila raven protiteles proti cirkovirusu PCV2 v krvi pujskov.